
Eleftherios P Mamounas MD
Breast, Surgical Oncology (Other than Breast)
Professor of Surgery, Northeast Ohio Medical University
Join to View Full Profile
2501 N Orange AveSte 389Orlando, FL 32804
Phone+1 407-303-5214
Fax+1 407-909-6944
Dr. Mamounas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- UPMC Medical Education (Pittsburgh)Residency, Surgery, 1984 - 1989
- University of AthensClass of 1983
Certifications & Licensure
- FL State Medical License 2012 - 2027
- OH State Medical License 1997 - 2014
- PA State Medical License 1985 - 1998
- American Board of Surgery Surgery
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Fluorescence Imaging of Carcinoma During Breast Conserving Surgery Start of enrollment: 2021 Apr 27
Roles: Principal Investigator
Publications & Presentations
PubMed
- NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer.Lior Z Braunstein, Melissa P Mitchell, Hanna Bandos, William M Sikov, Atif J Khan
Future Oncology. 2025-07-01 - Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy.Eleftherios P Mamounas, Hanna Bandos, Julia R White, Thomas B Julian, Atif J Khan
The New England Journal of Medicine. 2025-06-05 - 1 citationsBreast Tumor-Bed Biopsy for Pathological Complete Response Prediction: The NRG-BR005 Nonrandomized Clinical Trial.Mark Basik, Reena S Cecchini, Jennifer F De Los Santos, Heidi R Umphrey, Thomas B Julian
JAMA Surgery. 2025-05-07
Journal Articles
- 21-Gene Assay as Predictor of Chemotherapy Benefit in HER2-Negative Breast CancerEleftherios P Mamounas, Frederick L Baehner, Norman Wolmark, D Lawrence Wickerham, Nature
- Clinical Relevance of the 21-Gene Recurrence Score® Assay in Treatment Decisions for Patients with Node-Positive Breast Cancer in the Genomic EraEleftherios Mamounas, MD, Nature
Lectures
- NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to ...2019 ASCO Annual Meeting - 6/1/2019
- NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to ...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
- Regional Nodal Irradiation in Node-Negative Breast Cancer After Neoadjuvant ChemotherapyJune 18th, 2025
- NRG Oncology Study Finds Regional Nodal Irradiation Does Not Lower Invasive Breast Cancer Recurrence in Patients with Axillary Node Conversion After Neoadjuvant ChemotherapyJune 6th, 2025
- Nodal Irradiation Does Not Reduce Recurrence, Death for ypN0 Breast CancerJune 6th, 2025
- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: